Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
NCT ID: NCT07251998
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
172 participants
INTERVENTIONAL
2025-12-22
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICP-332 Dose A
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Dose B
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Dose C
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Placebo
ICP-332 Placebo Tablets
Placebo will be administered as tablet for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Placebo Tablets
Placebo will be administered as tablet for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female subjects aged ≥ 18 years and ≤ 70 years
3. A history of plaque psoriasis for ≥6 months at baseline
4. Meet the following three criteria:
1. Psoriasis Area and Severity Index (PASI) score ≥12
2. Static Physician's Global Assessment (sPGA) score ≥3
3. Psoriasis affected Body Surface Area (BSA) ≥10%
5. The subject requires systemic treatment and/or phototherapy.
Exclusion Criteria
2. Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
3. Presence of clinically serious, progressive, or uncontrolled disease.
4. Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
5. Pregnant or lactating women.
6. The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuling Shi
Role: PRINCIPAL_INVESTIGATOR
Shanghai Dermatology Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yuling Shi, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICP-CL-00603
Identifier Type: -
Identifier Source: org_study_id